Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

Look again @ Leronlimab (PRO 140) Combined With Ca

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 154899
(Total Views: 477)
Posted On: 07/05/2025 3:42:40 PM
Posted By: My69z
Look again @ Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC

Phase II:
The change from baseline in circulating tumor cells (CTC) level in the peripheral blood. [Time Frame: Every 21 days (i.e., Day 1 of each treatment cycle) through treatment completion, an average of 6 months.]

Phase II:
Progression Free Survival (PFS) according to RECIST v1.1 in participants with Detectable Programmed Death-Ligand 1 (PD-L1) [Time Frame: Every 6 to 9 weeks after study start, until progression or death, assessed up to 2 years after completion of treatment]
__
Aug. 12th. 2024 our current CRC:

The study will include a ** SAFETY LEAD-IN ** treating ** FIVE PATIENTS ** in the 350 mg leronlimab arm prior to beginning enrollment to the 700 mg leronlimab arm.
__
Leronlimab does no harm @ 350mg or 700 mg.
We of course know & so safe to say our current CRC is 1st 5 responding as safe.
__
Next CRC 20 @ 700 mg
2nd DSMB look.... safe.

Remaining 45 of our 60,
DSMB says @ 700 mg's
__
Cytodyn May 13th, 2025:
" CytoDyn’s results indicate that 15/17 (88%) of patients who received a weekly dose of 525 mg or higher experienced a significant increase in PD-L1 expression on their CTCs over a 30-to-90-day period after starting leronlimab."

2nd comment from the press release:
"The Company confirmed that 5/5 patients (100%) who demonstrated a significant increase in PD-L1 expression after receiving leronlimab and received treatment with any ICI remain alive today."
__
1. The protocol stopped CTC monitor after 6 months
2. PD-L1 observation out to 2 years

This shows Mgt. confidence that current CRC dosing @ 700 mg's, will easily be a lasting upregulating for later dosing an ICI.

Does May 13th, 2025 news kind of read they did 525 mg & ICI @ same time in those 30 - 90 days ?....or not ?

Or just referencing each, without saying @ what point in time they dosed an ICI?

A seperate ICI trial also makes sense because ICI effectiveness is not Cytodyn or Leronlimabs duty.

Like clearing an Hiv resevoir, we're giving ICI a job to do.

Maybe the Statistical Analysis Plan will have addtl info too about the trial overall after it's filed....

We're looking @ an LL / ICI combo potential of:

New SOC for all solid tumors.

Also creating access to massive untapped markets.


(5)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us